Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs.

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...

Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...

Telehealth firm 9amHealth has partnered with billionaire entrepreneur Mark Cuban's Cost Plus Drug Company to offer U.S.

VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.

Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish ...

Eli Lilly and Company (NYSE:LLY) may be affected by the CVS formulary change considering it could change how its medication, Zepbound, is viewed when compared to Wegovy. That said, despite possible ...